Post-Transfusion Purpura: Current Perspectives

References

• Savage W, Hod EA. Noninfectious complications of blood transfusion In: Fung M, editor. AABB Technical Manual. 19th ed. Bethesda, MD: AABB; 2017:569–597.
   Google Scholar
• Shtalrid M, Shvidel L, Vorst E, Weinmann EE, Berrebi A, Sigler E. Post-transfusion purpura: a challenging diagnosis. Isr Med Assoc J. 2006;8(10):672–674.17125110
   PubMed Web of Science ®Google Scholar
• Padhi P, Parihar GS, Stepp J, Kaplan R. Post-transfusion purpura: a rare and life-threatening aetiology of thrombocytopenia. BMJ Case Rep. 2013;2013:bcr2013008860.
   PubMedGoogle Scholar
• Shulman NR, Aster RH, Leitner A, Hiller MC. Immunoreactions involving platelets. V. Post-transfusion purpura due to a complement-fixing antibody against a genetically controlled platelet antigen. A proposed mechanism for thrombocytopenia and its relevance in “autoimmunity”. J Clin Invest. 1961;40(9):1597–1620. doi:10.1172/JCI10438316695867
   PubMed Web of Science ®Google Scholar
• Menis M, Forshee RA, Anderson SA, et al. Posttransfusion purpura occurrence and potential risk factors among the inpatient US elderly, as recorded in large medicare databases during 2011 through 2012. Transfusion. 2015;55(2):284–295. doi:10.1111/trf.v55.225065878
   PubMed Web of Science ®Google Scholar
• Taaning E, Svejgaard A. Post-transfusion purpura: a survey of 12 Danish cases with special reference to immunoglobulin G subclasses of the platelet antibodies. Transfus Med. 1994;4(1):1–8. doi:10.1111/j.1365-3148.1994.tb00236.x
   Web of Science ®Google Scholar
• Padmanabhan A, Connelly-Smith L, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice – evidence-based approach from the writing committee of the american society for apheresis: the eighth special issue. J Clin Apher. 2019;34(3):171–354.31180581
   PubMed Web of Science ®Google Scholar
• Lynce F, Yin F, Alcorn K, Malkovska V. Post-transfusion purpura in an African-American man due to human platelet antigen-5b alloantibody: a case report. J Med Case Rep. 2012;6:420. doi:10.1186/1752-1947-6-42023234542
   PubMedGoogle Scholar
• Williamson LM, Stainsby D, Jones H, et al. The impact of universal leukodepletion of the blood supply on hemovigilance reports of posttransfusion purpura and transfusion-associated graft-versus-host disease. Transfusion. 2007;47(8):1455–1467. doi:10.1111/trf.2007.47.issue-817655590
   PubMed Web of Science ®Google Scholar
• Rahman M, Ortega-Lopez A, Powers A. Sudden development of thrombocytopenia after reversal of anticoagulation for surgery. Lab Med. 2016;47(1):48–51. doi:10.1093/labmed/lmv00526715615
   PubMed Web of Science ®Google Scholar
• Van Loghem JJ, Dorfmeijer H, Van Hart M, Schreuder F. Serological and genetical studies on a platelet antigen (Zw). Vox Sang. 1959;4(2):161–169. doi:10.1159/00047846513669430
   PubMedGoogle Scholar
• Shulman NR. Immunoreactions involving platelets. I. A steric and kinetic model for formation of a complex from a human antibody, quinidine as a haptene, and platelets; and for fixation of complement by the complex. J Exp Med. 1958;107(5):665–690. doi:10.1084/jem.107.5.66513525578
   PubMed Web of Science ®Google Scholar
• Pegels JG, Bruynes EC, Engelfriet CP, von dem Borne AE. Post-transfusion purpura: a serological and immunochemical study. Br J Haematol. 1981;49(4):521–530. doi:10.1111/j.1365-2141.1981.tb07260.x7198482
   PubMed Web of Science ®Google Scholar
• Lillicrap DP, Ford PM, Giles AR. Prolonged thrombocytopenia in post-transfusion purpura (PTP) associated with changes in the crossed immunoelectrophoretic pattern of von Willebrand factor (vWF), circulating immune complexes and endothelial cell cytotoxicity. Br J Haematol. 1986;62(1):37–46. doi:10.1111/j.1365-2141.1986.tb02898.x3484637
   PubMed Web of Science ®Google Scholar
• Kickler TS, Ness PM, Herman JH, Bell WR. Studies on the pathophysiology of posttransfusion purpura. Blood. 1986;68(2):347–350. doi:10.1182/blood.V68.2.347.3473524706
   PubMed Web of Science ®Google Scholar
• Falk G, Winans CG, Bowens K, Bougie DW, Curtis BR, Aster RH. An unexpected development after surgery-post-transfusion purpura! Am J Hematol. 2016;91(8):848–851. doi:10.1002/ajh.2441427159228
   PubMed Web of Science ®Google Scholar
• von dem Borne AE, van der Plas-van Dalen CM. Further observation on post-transfusion purpura (PTP). Br J Haematol. 1985;61(2):374–375. doi:10.1111/j.1365-2141.1985.tb02838.x4041380
   PubMed Web of Science ®Google Scholar
• Cunningham CC, Lind SE. Apparent response of refractory post-transfusion purpura to splenectomy. Am J Hematol. 1989;30(2):112–113. doi:10.1002/(ISSN)1096-86522913759
   PubMed Web of Science ®Google Scholar
• McFarland J. Post transfusion purpura In: Popovsky M, editor. Transfusion Reactions. 4th ed. Bethesda, MD: AABB Press; 2012:263–287.
   Google Scholar
• Neunert CE. Management of newly diagnosed immune thrombocytopenia: can we change outcomes? Blood Adv. 2017;1(24):2295–2301. doi:10.1182/bloodadvances.201700986029296878
   PubMed Web of Science ®Google Scholar
• Minchinton RM, Cunningham I, Cole-Sinclair M, Van der Weyden M, Vaughan S, McGrath KM. Autoreactive platelet antibody in post transfusion purpura. Aust N Z J Med. 1990;20(2):111–115. doi:10.1111/imj.1990.20.issue-22188642
   PubMedGoogle Scholar
• Taaning E, Tonnesen F. Pan-reactive platelet antibodies in post-transfusion purpura. Vox Sang. 1999;76(2):120–123. doi:10.1046/j.1423-0410.1999.7620120.x10085529
   PubMed Web of Science ®Google Scholar
• Berney SI, Metcalfe P, Wathen NC, Waters AH. Post-transfusion purpura responding to high dose intravenous IgG: further observations on pathogenesis. Br J Haematol. 1985;61(4):627–632. doi:10.1111/j.1365-2141.1985.tb02876.x4084453
   PubMed Web of Science ®Google Scholar
• Gerstner JB, Smith MJ, Davis KD, Cimo PL, Aster RH. Posttransfusion purpura: therapeutic failure of PlAl-negative platelet transfusion. Am J Hematol. 1979;6(1):71–75. doi:10.1002/(ISSN)1096-8652572138
   PubMed Web of Science ®Google Scholar
• Brighton TA, Evans S, Castaldi PA, Chesterman CN, Chong BH. Prospective evaluation of the clinical usefulness of an antigen-specific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias. Blood. 1996;88(1):194–201. doi:10.1182/blood.V88.1.194.1948704174
   PubMed Web of Science ®Google Scholar
• Warner MN, Moore JC, Warkentin TE, Santos AV, Kelton JG. A prospective study of protein-specific assays used to investigate idiopathic thrombocytopenic purpura. Br J Haematol. 1999;104(3):442–447. doi:10.1046/j.1365-2141.1999.01218.x10086776
   PubMed Web of Science ®Google Scholar
• Davoren A, Bussel J, Curtis BR, Moghaddam M, Aster RH, McFarland JG. Prospective evaluation of a new platelet glycoprotein (GP)-specific assay (PakAuto) in the diagnosis of autoimmune thrombocytopenia (AITP). Am J Hematol. 2005;78(3):193–197. doi:10.1002/(ISSN)1096-865215726595
   PubMed Web of Science ®Google Scholar
• Tan GC, Stalling M, Dennis G, Nunez M, Kahwash SB. Pseudothrombocytopenia due to platelet clumping: a case report and brief review of the literature. Case Rep Hematol. 2016;2016:3036476. doi:10.1155/2016/303647628044112
   PubMedGoogle Scholar
• Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2Suppl):e495S–e530S. doi:10.1378/chest.11-230322315270
   PubMed Web of Science ®Google Scholar
• Lubenow N, Eichler P, Albrecht D, et al. Very low platelet counts in post-transfusion purpura falsely diagnosed as heparin-induced thrombocytopenia. Report of four cases and review of literature. Thromb Res. 2000;100(3):115–125. doi:10.1016/S0049-3848(00)00311-X11108897
   PubMed Web of Science ®Google Scholar
• Human Platelet Antigen (HPA) database. Versiti. Available from: https://www.versiti.org/medical-professionals/precision-medicine-expertise/platelet-antigen-database#hpa-database.Accessed 1029, 2019.
   Google Scholar
• Heikal NM, Smock KJ. Laboratory testing for platelet antibodies. Am J Hematol. 2013;88(9):818–821. doi:10.1002/ajh.v88.923757218
   PubMed Web of Science ®Google Scholar
• Kim H, Oh EJ, Kim J, Park YJ, Han K. Detection of platelet specific antibodies by modified antigen capture ELISA test. Korean J Lab Med. 2006;26(3):192–197. doi:10.3343/kjlm.2006.26.3.19218156724
   PubMedGoogle Scholar
• Lochowicz AJ, Curtis BR. Clinical applications of platelet antibody and antigen testing. Lab Med. 2011;42(11):687–692. doi:10.1309/LMM242GKGHCKJRWI
   Web of Science ®Google Scholar
• Kiefel V, Santoso S, Weisheit M, Mueller-Eckhardt C. Monoclonal antibody–specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies. Blood. 1987;70(6):1722–1726. doi:10.1182/blood.V70.6.1722.17222445398
   PubMed Web of Science ®Google Scholar
• Metzner K, Bauer J, Ponzi H, Ujcich A, Curtis BR. Detection and identification of platelet antibodies using a sensitive multiplex assay system-platelet antibody bead array. Transfusion. 2017;57(7):1724–1733. doi:10.1111/trf.2017.57.issue-728439930
   PubMed Web of Science ®Google Scholar
• Porcelijn L, Huiskes E, Comijs-van Osselen I, et al. A new bead-based human platelet antigen antibodies detection assay versus the monoclonal antibody immobilization of platelet antigens assay. Transfusion. 2014;54(6):1486–1492. doi:10.1111/trf.1250924299453
   PubMed Web of Science ®Google Scholar
• Kakaiya RM, Triulzi DJ, Wright DJ, et al. Prevalence of HLA antibodies in remotely transfused or alloexposed volunteer blood donors. Transfusion. 2010;50(6):1328–1334. doi:10.1111/trf.2010.50.issue-620070615
   PubMed Web of Science ®Google Scholar
• Triulzi DJ, Kleinman S, Kakaiya RM, et al. The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: implications for a transfusion-related acute lung injury risk reduction strategy. Transfusion. 2009;49(9):1825–1835. doi:10.1111/j.1537-2995.2009.02206.x19453983
   PubMed Web of Science ®Google Scholar
• Curtis BR, McFarland JG. Human platelet antigens – 2013. Vox Sang. 2014;106(2):93–102. doi:10.1111/vox.1208524102564
   PubMed Web of Science ®Google Scholar
• Davey S, Navarrete C, Brown C. Simultaneous human platelet antigen genotyping and detection of novel single nucleotide polymorphisms by targeted next-generation sequencing. Transfusion. 2017;57(6):1497–1504. doi:10.1111/trf.2017.57.issue-628370162
   PubMed Web of Science ®Google Scholar
• Vaughan-Neil EF, Ardeman S, Bevan G, Blakeman AC, Jenkins WJ. Post-transfusion purpura associated with unusual platelet antibody (anti-Pl-B1). Br Med J. 1975;1(5955):436–437. doi:10.1136/bmj.1.5955.4361115962
   PubMed Web of Science ®Google Scholar
• McCrae KR, Herman JH. Posttransfusion purpura: two unusual cases and a literature review. Am J Hematol. 1996;52(3):205–211. doi:10.1002/(ISSN)1096-86528756089
   PubMed Web of Science ®Google Scholar
• Pavenski K, Webert KE, Goldman M. Consequences of transfusion of platelet antibody: a case report and literature review. Transfusion. 2008;48(9):1981–1989. doi:10.1111/trf.2008.48.issue-918564398
   PubMed Web of Science ®Google Scholar
• Bolton-Maggs PH, Cohen H. Serious hazards of transfusion (SHOT) haemovigilance and progress is improving transfusion safety. Br J Haematol. 2013;163(3):303–314. doi:10.1111/bjh.1254724032719
   PubMed Web of Science ®Google Scholar
• Prowse CV, Hornsey VS, Drummond O, et al. Preliminary assessment of whole-blood, red-cell and platelet-leucodepleting filters for possible induction of prion release by leucocyte fragmentation during room temperature processing. Br J Haematol. 1999;106(1):240–247. doi:10.1046/j.1365-2141.1999.01530.x10444194
   PubMed Web of Science ®Google Scholar
• Almizraq RJ, Norris PJ, Inglis H, et al. Blood manufacturing methods affect red blood cell product characteristics and immunomodulatory activity. Blood Adv. 2018;2(18):2296–2306. doi:10.1182/bloodadvances.201802193130217795
   PubMed Web of Science ®Google Scholar
• Pivalizza EG, Stephens CT, Sridhar S, et al. Whole blood for resuscitation in adult civilian Trauma in 2017: a narrative review. Anesth Analg. 2018;127(1):157–162. doi:10.1213/ANE.000000000000342729771715
   PubMed Web of Science ®Google Scholar
• Spinella PC, Dressler A, Tucci M, et al. Survey of transfusion policies at US and Canadian children’s hospitals in 2008 and 2009. Transfusion. 2010;50(11):2328–2335. doi:10.1111/trf.2010.50.issue-1120529008
   PubMed Web of Science ®Google Scholar
• Holcomb JB, Jenkins DH. Get ready: whole blood is back and it’s good for patients. Transfusion. 2018;58(8):1821–1823. doi:10.1111/trf.1481830144081
   PubMed Web of Science ®Google Scholar
• Seheult JN, Anto V, Alarcon LH, Sperry JL, Triulzi DJ, Yazer MH. Clinical outcomes among low-titer group O whole blood recipients compared to recipients of conventional components in civilian trauma resuscitation. Transfusion. 2018;58(8):1838–1845. doi:10.1111/trf.1477930160310
   PubMed Web of Science ®Google Scholar
• Mueller-Eckhardt C, Kuenzlen E, Thilo-Korner D, Pralle H. High-dose intravenous immunoglobulin for post-transfusion purpura. N Engl J Med. 1983;308(5):287.
   PubMed Web of Science ®Google Scholar
• Becker T, Panzer S, Maas D, et al. High-dose intravenous immunoglobulin for post-transfusion purpura. Br J Haematol. 1985;61(1):149–155. doi:10.1111/j.1365-2141.1985.tb04071.x4052323
   PubMed Web of Science ®Google Scholar
• Hamblin TJ, Naorose Abidi SM, Nee PA, Copplestone A, Mufti GJ, Oscier DG. Successful treatment of post-transfusion purpura with high dose immunoglobulins after lack of response to plasma exchange. Vox Sang. 1985;49(2):164–167. doi:10.1159/0004663654036084
   PubMed Web of Science ®Google Scholar
• Slichter SJ. Post-transfusion purpura: response to steroids and association with red blood cell and lymphocytotoxic antibodies. Br J Haematol. 1982;50(4):599–605. doi:10.1111/j.1365-2141.1982.tb01960.x7199931
   PubMed Web of Science ®Google Scholar
• Christie DJ, Pulkrabek S, Putnam JL, Slatkoff ML, Pischel KD. Posttransfusion purpura due to an alloantibody reactive with glycoprotein Ia/IIa (anti-HPA-5b). Blood. 1991;77(12):2785–2789. doi:10.1182/blood.V77.12.2785.27852043772
   PubMed Web of Science ®Google Scholar
• Vogelsang G, Kickler TS, Bell WR. Post-transfusion purpura: a report of five patients and a review of the pathogenesis and management. Am J Hematol. 1986;21(3):259–267. doi:10.1002/(ISSN)1096-86523946408
   PubMed Web of Science ®Google Scholar
• Cimo PL, Aster RH. Post-transfusion purpura: successful treatment by exchange transfusion. N Engl J Med. 1972;287(6):290–292. doi:10.1056/NEJM1972081028706085038955
   PubMed Web of Science ®Google Scholar
• Brecher ME, Moore SB, Letendre L. Posttransfusion purpura: the therapeutic value of PlA1-negative platelets. Transfusion. 1990;30(5):433–435. doi:10.1046/j.1537-2995.1990.30590296377.x2360235
   PubMed Web of Science ®Google Scholar
• Budd JL, Wiegers SE, O’Hara JM. Relapsing post-transfusion purpura. A preventable disease. Am J Med. 1985;78(2):361–362. doi:10.1016/0002-9343(85)90451-64038575
   PubMed Web of Science ®Google Scholar
• Puig N, Sayas MJ, Montoro JA, Villalba JV, Pla A. Post-transfusion purpura as the main manifestation of a trilineal transfusion reaction, responsive to steroids: flow-cytometric investigation of granulocyte and platelet antibodies. Ann Hematol. 1991;62(6):232–234. doi:10.1007/BF017298391854887
   PubMed Web of Science ®Google Scholar
• Godeau B, Fromont P, Bettaieb A, Duedari N, Bierling P. Post-transfusion purpura. An unknown cause of acute immune thrombocytopenia. 4 new cases]. Presse Med. 1990;19(43):1974–1977.2149598
   PubMed Web of Science ®Google Scholar
• Vincent EC, Willett T. Post-transfusion purpura. J Am Board Fam Pract. 1991;4(3):175–177.1810275
   PubMedGoogle Scholar
• Immunologic transfusion reactions. Eds. Jennifer S Tirnauer; 2019 Available from: https://www.uptodate.com/contents/immunologic-transfusion-reactions?search=post%20transfusion%20purpura§ionRank=1&usage_type=default&anchor=H18&source=machineLearning&selectedTitle=1~12&display_rank=1#H18. Accessed 715, 2019.
   Google Scholar
• Page EE, Kremer Hovinga JA, Terrell DR, Vesely SK, George JN. Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015. Blood Adv. 2017;1(10):590–600. doi:10.1182/bloodadvances.201700512429296701
   PubMed Web of Science ®Google Scholar
• Warkentin TE. Low-molecular weight heparins in prophylaxis and therapy of thromboembolic diseases In: Bounameaux H, editor. Low-Molecular Weight Heparins in Prophylaxis and Therapy of Thromboembolic Diseases. New York: Marcel Dekker; 1994:75.
   Google Scholar
• Warkentin TE. Clinical presentation of heparin-induced thrombocytopenia. Semin Hematol. 1998;35(4Suppl 5):9–16.
   Google Scholar
• Ortel TL. Heparin-induced thrombocytopenia: when a low platelet count is a mandate for anticoagulation. Hematology Am Soc Hematol Educ Program. 2009;2009:225–232. doi:10.1182/asheducation-2009.1.225
   Google Scholar
• Aster RH, Curtis BR, McFarland JG, Bougie DW. Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management. J Thromb Haemost. 2009;7(6):911–918. doi:10.1111/jth.2009.7.issue-619344362
   PubMed Web of Science ®Google Scholar
• Scully M, Yarranton H, Liesner R, et al. Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features. Br J Haematol. 2008;142(5):819–826. doi:10.1111/bjh.2008.142.issue-518637802
   PubMed Web of Science ®Google Scholar
• Jamme M, Rondeau E. The PLASMIC score for thrombotic thrombocytopenic purpura. Lancet Haematol. 2017;4(4):e148–e149. doi:10.1016/S2352-3026(17)30024-828259521
   PubMed Web of Science ®Google Scholar
• Bendapudi PK, Hurwitz S, Fry A, et al. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. Lancet Haematol. 2017;4(4):. doi:10.1016/S2352-3026(17)30026-1
   Web of Science ®Google Scholar
• Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T’s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006;4(4):759–765. doi:10.1111/jth.2006.4.issue-416634744
   PubMed Web of Science ®Google Scholar
• Cuker A, Gimotty PA, Crowther MA, Warkentin TE. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood. 2012;120(20):4160–4167. doi:10.1182/blood-2012-07-44305122990018
   PubMed Web of Science ®Google Scholar
• Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190–4207. doi:10.1182/blood-2010-08-30298421325604
   PubMed Web of Science ®Google Scholar
• Al-Samkari H, Kuter DJ. Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia. Ther Adv Hematol. 2019;10:2040620719841735. doi:10.1177/204062071984173531007886
   PubMed Web of Science ®Google Scholar
• Scully M, Cataland SR, Peyvandi F, et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019;380(4):335–346. doi:10.1056/NEJMoa180631130625070
   PubMed Web of Science ®Google Scholar
• Cuker A, Arepally GM, Chong BH, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018;2(22):3360–3392. doi:10.1182/bloodadvances.201802448930482768
   PubMed Web of Science ®Google Scholar